CASPOFUNGIN FOR INJECTION POWDER FOR SOLUTION

Land: Kanada

Språk: engelska

Källa: Health Canada

Aktiva substanser:

CASPOFUNGIN (CASPOFUNGIN ACETATE)

Tillgänglig från:

JUNO PHARMACEUTICALS CORP.

ATC-kod:

J02AX04

INN (International namn):

CASPOFUNGIN

Dos:

50MG

Läkemedelsform:

POWDER FOR SOLUTION

Sammansättning:

CASPOFUNGIN (CASPOFUNGIN ACETATE) 50MG

Administreringssätt:

INTRAVENOUS

Enheter i paketet:

15G/50G

Receptbelagda typ:

Prescription

Terapiområde:

ECHINOCANDINS

Produktsammanfattning:

Active ingredient group (AIG) number: 0144763001; AHFS:

Bemyndigande status:

APPROVED

Tillstånd datum:

2017-04-18

Produktens egenskaper

_Caspofungin for Injection_
_Page 1 of 50_
PRODUCT MONOGRAPH
Pr
.
CASPOFUNGIN FOR INJECTION
50 mg/vial, 70 mg/vial
Caspofungin (as caspofungin acetate)
Antifungal
JUNO PHARMACEUTICALS CORP.
402-2233 Argentia Road
Mississauga, ON
L5N 2X7
DATE OF PREPARATION:
May 21, 2021
SUBMISSION CONTROL NUMBER: 247611
_Caspofungin for Injection_
_Page 2 of 50_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
DESCRIPTION
............................................................................................................
3
INDICATIONS AND CLINICAL
USE.........................................................................
3
CONTRAINDICATIONS.............................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................
4
ADVERSE REACTIONS
.............................................................................................
7
DRUG INTERACTIONS
............................................................................................21
DOSAGE AND
ADMINISTRATION..........................................................................22
OVERDOSAGE..........................................................................................................28
ACTION AND CLINICAL PHARMACOLOGY
.........................................................29
STORAGE AND
STABILITY.....................................................................................30
DOSAGE FORMS, COMPOSITION AND PACKAGING
...........................................30
PART II: SCIENTIFIC
INFORMATION...........................................................................
32
PHARMACEUTICAL INFORMATION
.....................................................................32
CLINICAL
TRIALS...................................................................................